Global Oral Weight Loss Drug Market Growth (Status and Outlook) 2026-2032
The global Oral Weight Loss Drug market size is predicted to grow from US$ 2789 million in 2025 to US$ 23930 million in 2032; it is expected to grow at a CAGR of 29.8% from 2026 to 2032.
The Oral Weight Loss Drug market covers pharmaceutical products formulated for oral administration and developed for body-weight reduction, obesity treatment, and long-term weight management. The research scope comprises marketed and investigational tablets, immediate-release and extended-release tablets, hard capsules, extended-release capsules, and other oral solid dosage forms. Products are differentiated by mechanisms including GLP-1 receptor agonism, dual GLP-1/GIP receptor agonism, gastrointestinal lipase inhibition, sympathomimetic appetite suppression, central appetite and reward-pathway modulation, MGAT2 inhibition, and other metabolic pathways. Both single-ingredient drugs and fixed-dose combinations are covered, together with originator and branded products, generic drugs, and investigational candidates. Principal clinical applications include adult obesity, overweight accompanied by weight-related comorbidities, adolescent obesity, obesity associated with type 2 diabetes, short-term weight reduction, long-term chronic weight management, and weight maintenance following initial treatment. The market is evaluated according to therapeutic mechanism, formulation, clinical positioning, regulatory status, patient population, treatment duration, and commercialization model.
Key Findings
The average gross profit margin of this product is 75%
Oral GLP-1 therapies are reshaping the overall product mix
Legacy small molecules retain relevance in cost-sensitive treatment pathways
Once-daily tablets broaden options beyond injectable obesity treatment
North America leads commercialization of next-generation oral therapies
Safety tolerability and persistence determine long-term market value
Market Trends
The Oral Weight Loss Drug market is entering a structural transition from conventional appetite suppressants, gastrointestinal lipase inhibitors, and fixed-dose central nervous system combinations toward incretin-based oral therapies and other metabolically targeted small molecules. The approval and commercialization of once-daily oral semaglutide and orforglipron in the United States have demonstrated that oral products can provide clinically meaningful chronic weight-management options within a therapeutic field previously transformed by injectable GLP-1 products. Product development is now following two principal technical routes: peptide-based tablets supported by specialized absorption-enhancing formulations and non-peptide small-molecule receptor agonists designed for conventional oral administration. At the same time, development programs targeting dual receptors, intestinal lipid metabolism, appetite regulation, and combination mechanisms are widening the innovation pipeline. Customer demand is also moving away from temporary weight reduction toward sustained obesity management, maintenance of treatment response, and management of cardiometabolic comorbidities. Consequently, differentiation increasingly depends on efficacy, gastrointestinal tolerability, dosing flexibility, food-related administration requirements, treatment persistence, and evidence supporting broader metabolic benefits rather than weight loss alone.
Market Dynamics
Drivers
The principal demand driver is the expanding population affected by obesity and overweight-related metabolic disorders, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, and other chronic conditions. Obesity is increasingly managed as a long-duration disease rather than a short-term lifestyle issue, supporting recurring pharmacological treatment and weight-maintenance demand. Oral dosage forms may broaden the addressable patient population by reducing injection-related barriers, fitting established retail-pharmacy and primary-care workflows, and offering patients a familiar administration format. The emergence of oral therapies with stronger weight-reduction profiles has also increased physician and patient interest in pharmaceutical intervention. Regulatory recognition of chronic weight management and broader cardiometabolic outcomes is encouraging investment in differentiated oral mechanisms, while competition among pharmaceutical groups is accelerating clinical development, manufacturing scale-up, and commercial education. These factors collectively support expansion across newly treated patients, individuals switching from older oral agents, and patients seeking alternatives to injectable therapy.
Restraints
Market development remains constrained by safety, tolerability, access, and treatment-persistence issues. Gastrointestinal adverse reactions, gradual dose-escalation requirements, contraindications, drug interactions, and mechanism-specific warnings may restrict product suitability or result in discontinuation. Some older oral therapies offer moderate weight-loss efficacy relative to newer incretin-based products, while innovative therapies may face affordability and reimbursement barriers that limit penetration among cost-sensitive populations. Oral administration does not automatically eliminate adherence challenges because patients must continue treatment over extended periods, comply with dietary and physical-activity recommendations, and follow product-specific dosing instructions. Peptide tablets may also require technically demanding formulation and administration conditions, while novel small molecules must establish durable efficacy and acceptable long-term safety. Uneven insurance coverage and differences in national obesity-treatment policies further create a gap between clinical eligibility and actual commercial access.
Opportunities
The most significant opportunity lies in expanding oral pharmacotherapy from a limited selection of legacy agents into a broader portfolio of high-efficacy chronic weight-management products. Small-molecule GLP-1 receptor agonists provide potential advantages in manufacturing scalability, storage, transportation, and administration flexibility, while peptide tablets create opportunities to extend established incretin platforms into needle-free formats. Additional potential exists in GLP-1/GIP dual receptor agonists, MGAT2 inhibitors, differentiated appetite-regulation pathways, and fixed-dose combinations designed to improve efficacy or address multiple metabolic mechanisms. Products optimized for patients with type 2 diabetes, cardiovascular risk, or other weight-related comorbidities may generate greater clinical value than products positioned only for general weight reduction. Further opportunities are expected in adolescent obesity, long-term weight maintenance, emerging markets with limited access to injectable therapies, and lower-cost generic or differentiated branded products. Companies capable of balancing efficacy, tolerability, dosing convenience, and affordability are positioned to reach patient groups not adequately served by current treatment options.
Challenges
Long-term commercial success will require more than demonstrating statistically significant weight reduction. Developers must establish clinically meaningful differentiation against rapidly improving oral and injectable standards of care, while generating sufficient evidence on treatment durability, safety, discontinuation effects, cardiometabolic outcomes, and use in diverse patient groups. Clinical trials are increasingly expensive and complex as regulators, physicians, and payers seek longer follow-up and broader outcome measures. Companies must also manage large-scale active ingredient production, formulation consistency, quality control, and demand forecasting without compromising regulatory compliance. Competitive intensity may shorten product differentiation cycles and increase marketing, patient-support, and contracting expenditure. Meanwhile, public concern regarding inappropriate cosmetic use, unapproved compounded products, adverse-event management, and unequal access may lead to additional regulatory scrutiny. The market therefore presents substantial demand potential but also requires sustained clinical investment, manufacturing discipline, and carefully managed commercialization.
Industry Chain Analysis
The upstream chain of the Oral Weight Loss Drug market comprises peptide and small-molecule active pharmaceutical ingredients, chemical intermediates, absorption-enhancing agents, release-controlling materials, pharmaceutical-grade excipients, capsule shells, and packaging materials. Technical requirements differ significantly by mechanism. Oral peptide products require specialized formulation strategies to protect active ingredients and improve gastrointestinal absorption, whereas non-peptide small molecules depend more heavily on medicinal chemistry optimization, scalable synthesis, impurity control, and conventional solid-dose manufacturing. Fixed-dose combinations and extended-release products additionally require compatibility studies and release-profile control. The availability, quality, regulatory status, and cost of active ingredients therefore have a direct influence on manufacturing economics and supply reliability.
Midstream activities cover formulation development, tablet compression or capsule filling, coating, analytical testing, clinical development, regulatory registration, commercial manufacturing, and pharmacovigilance. Downstream value is realized through hospitals, specialist clinics, primary-care providers, retail and specialty pharmacies, digital weight-management platforms, and structured chronic-care programs. Innovative originator products capture value through differentiated clinical evidence, intellectual property, brand recognition, and physician adoption, while established brands and generic products compete more strongly through manufacturing efficiency, pricing, channel coverage, and patient accessibility. Across the value chain, the highest barriers are concentrated in mechanism validation, late-stage clinical development, regulatory approval, scalable formulation, and evidence generation supporting long-term treatment value.
Segment Insights
By therapeutic mechanism, GLP-1 receptor agonists have become the most strategically important innovation segment because they narrow the efficacy gap between oral and injectable obesity therapies. Within this category, peptide tablets and small-molecule agonists represent distinct technological and commercial models. Peptide-based products benefit from established incretin biology but require sophisticated absorption technology, while small molecules may provide greater administration flexibility and conventional manufacturing potential. GLP-1/GIP dual receptor agonists and other multi-pathway products represent an emerging development direction, although clinical differentiation and safety remain decisive. Gastrointestinal lipase inhibitors, sympathomimetic appetite suppressants, naltrexone/bupropion combinations, and phentermine/topiramate combinations retain market relevance through established prescribing experience, generic availability, or differentiated patient suitability.
By product class, single-ingredient drugs provide clearer mechanism positioning and simpler clinical evaluation, whereas fixed-dose combinations seek complementary effects through multiple pathways. Originator and branded products account for most innovation value, while generic drugs serve price-sensitive and access-constrained markets. Investigational drugs form an increasingly diverse pipeline covering receptor agonism, intestinal lipid metabolism, and central appetite control. From a dosage-form perspective, immediate-release tablets provide manufacturing simplicity, while extended-release tablets and capsules support controlled exposure and may improve dosing convenience for selected mechanisms. Competitive advantage within each segment will depend on the balance between weight reduction, tolerability, administration requirements, treatment persistence, and total patient cost.
Downstream Market Opportunities
Adult obesity and overweight accompanied by weight-related comorbidities constitute the principal clinical opportunity for Oral Weight Loss Drug products. Within this population, patients with type 2 diabetes, cardiovascular risk factors, dyslipidemia, hypertension, or other metabolic complications may derive particular value from therapies that address both body weight and broader metabolic outcomes. Long-term chronic weight management and maintenance following initial weight reduction are becoming more important than episodic treatment, increasing demand for products with acceptable tolerability and convenient daily administration. Adolescent obesity represents an additional opportunity, although regulatory requirements, safety considerations, and family-supported adherence are more demanding. Oral products may also expand treatment among patients unwilling or unable to use injectable drugs and in healthcare systems where pharmacy-based distribution and primary-care management are more scalable than specialist-led injection programs.
Regional Insights
North America currently represents the most commercially advanced market for next-generation Oral Weight Loss Drug products, supported by early regulatory approvals, established obesity-treatment channels, substantial patient awareness, and rapid commercialization of oral GLP-1 therapies. The United States became the first major market to approve and launch once-daily oral semaglutide for weight management, followed by approval of the small-molecule GLP-1 receptor agonist orforglipron in 2026. This early market access provides important evidence regarding prescription uptake, patient segmentation, pricing, persistence, and competition with injectable products.
Europe offers meaningful demand but is more strongly influenced by health-technology assessment, national reimbursement decisions, prescribing controls, and differences among healthcare systems. Asia-Pacific represents an important longer-term opportunity due to a large population affected by obesity and metabolic disease, expanding domestic drug-development activity, and demand for more accessible oral treatment. China is developing into both a clinical-development base and a potential commercialization market for innovative oral mechanisms, although pricing, reimbursement, regulatory differentiation, and physician education will shape adoption. In other regions, market expansion will depend on affordability, diagnosis rates, healthcare access, and the ability of suppliers to establish reliable local distribution.
Competitive Landscape Analysis
The competitive landscape is transitioning from a relatively established market of gastrointestinal lipase inhibitors, appetite suppressants, and fixed-dose combination products into a broader innovation race involving oral incretin therapies and new metabolic mechanisms. Novo Nordisk and Eli Lilly have established early commercial positions in next-generation oral GLP-1 treatment through approved once-daily products, raising expectations for efficacy and chronic-treatment value. Established oral brands continue to compete through physician familiarity, lower treatment costs, generic availability, and defined patient niches. At the same time, diversified pharmaceutical groups and clinical-stage biotechnology companies in the confirmed participant set are advancing oral GLP-1 receptor agonists, dual receptor candidates, MGAT2 inhibitors, and other mechanism-based products. Competitive positioning is therefore becoming multi-dimensional: leading companies require clinical efficacy and safety data, scalable manufacturing, regulatory execution, reimbursement access, brand credibility, and patient-support capabilities. Companies with less differentiated efficacy may compete through tolerability, flexible administration, combination strategies, regional pricing, or access advantages. As additional candidates progress, head-to-head evidence and real-world treatment persistence are expected to become increasingly important determinants of commercial positioning.
Report Scope
LPI (LP Information)' newest research report, the “Oral Weight Loss Drug Industry Forecast” looks at past sales and reviews total world Oral Weight Loss Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Weight Loss Drug sales for 2026 through 2032. With Oral Weight Loss Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Weight Loss Drug industry.
This Insight Report provides a comprehensive analysis of the global Oral Weight Loss Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Weight Loss Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Weight Loss Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Weight Loss Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Weight Loss Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Weight Loss Drug market by product type, application, key players and key regions and countries.
Market Segmentation
The Oral Weight Loss Drug market covers pharmaceutical products formulated for oral administration and developed for body-weight reduction, obesity treatment, and long-term weight management. The research scope comprises marketed and investigational tablets, immediate-release and extended-release tablets, hard capsules, extended-release capsules, and other oral solid dosage forms. Products are differentiated by mechanisms including GLP-1 receptor agonism, dual GLP-1/GIP receptor agonism, gastrointestinal lipase inhibition, sympathomimetic appetite suppression, central appetite and reward-pathway modulation, MGAT2 inhibition, and other metabolic pathways. Both single-ingredient drugs and fixed-dose combinations are covered, together with originator and branded products, generic drugs, and investigational candidates. Principal clinical applications include adult obesity, overweight accompanied by weight-related comorbidities, adolescent obesity, obesity associated with type 2 diabetes, short-term weight reduction, long-term chronic weight management, and weight maintenance following initial treatment. The market is evaluated according to therapeutic mechanism, formulation, clinical positioning, regulatory status, patient population, treatment duration, and commercialization model.
Key Findings
The average gross profit margin of this product is 75%
Oral GLP-1 therapies are reshaping the overall product mix
Legacy small molecules retain relevance in cost-sensitive treatment pathways
Once-daily tablets broaden options beyond injectable obesity treatment
North America leads commercialization of next-generation oral therapies
Safety tolerability and persistence determine long-term market value
Market Trends
The Oral Weight Loss Drug market is entering a structural transition from conventional appetite suppressants, gastrointestinal lipase inhibitors, and fixed-dose central nervous system combinations toward incretin-based oral therapies and other metabolically targeted small molecules. The approval and commercialization of once-daily oral semaglutide and orforglipron in the United States have demonstrated that oral products can provide clinically meaningful chronic weight-management options within a therapeutic field previously transformed by injectable GLP-1 products. Product development is now following two principal technical routes: peptide-based tablets supported by specialized absorption-enhancing formulations and non-peptide small-molecule receptor agonists designed for conventional oral administration. At the same time, development programs targeting dual receptors, intestinal lipid metabolism, appetite regulation, and combination mechanisms are widening the innovation pipeline. Customer demand is also moving away from temporary weight reduction toward sustained obesity management, maintenance of treatment response, and management of cardiometabolic comorbidities. Consequently, differentiation increasingly depends on efficacy, gastrointestinal tolerability, dosing flexibility, food-related administration requirements, treatment persistence, and evidence supporting broader metabolic benefits rather than weight loss alone.
Market Dynamics
Drivers
The principal demand driver is the expanding population affected by obesity and overweight-related metabolic disorders, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, and other chronic conditions. Obesity is increasingly managed as a long-duration disease rather than a short-term lifestyle issue, supporting recurring pharmacological treatment and weight-maintenance demand. Oral dosage forms may broaden the addressable patient population by reducing injection-related barriers, fitting established retail-pharmacy and primary-care workflows, and offering patients a familiar administration format. The emergence of oral therapies with stronger weight-reduction profiles has also increased physician and patient interest in pharmaceutical intervention. Regulatory recognition of chronic weight management and broader cardiometabolic outcomes is encouraging investment in differentiated oral mechanisms, while competition among pharmaceutical groups is accelerating clinical development, manufacturing scale-up, and commercial education. These factors collectively support expansion across newly treated patients, individuals switching from older oral agents, and patients seeking alternatives to injectable therapy.
Restraints
Market development remains constrained by safety, tolerability, access, and treatment-persistence issues. Gastrointestinal adverse reactions, gradual dose-escalation requirements, contraindications, drug interactions, and mechanism-specific warnings may restrict product suitability or result in discontinuation. Some older oral therapies offer moderate weight-loss efficacy relative to newer incretin-based products, while innovative therapies may face affordability and reimbursement barriers that limit penetration among cost-sensitive populations. Oral administration does not automatically eliminate adherence challenges because patients must continue treatment over extended periods, comply with dietary and physical-activity recommendations, and follow product-specific dosing instructions. Peptide tablets may also require technically demanding formulation and administration conditions, while novel small molecules must establish durable efficacy and acceptable long-term safety. Uneven insurance coverage and differences in national obesity-treatment policies further create a gap between clinical eligibility and actual commercial access.
Opportunities
The most significant opportunity lies in expanding oral pharmacotherapy from a limited selection of legacy agents into a broader portfolio of high-efficacy chronic weight-management products. Small-molecule GLP-1 receptor agonists provide potential advantages in manufacturing scalability, storage, transportation, and administration flexibility, while peptide tablets create opportunities to extend established incretin platforms into needle-free formats. Additional potential exists in GLP-1/GIP dual receptor agonists, MGAT2 inhibitors, differentiated appetite-regulation pathways, and fixed-dose combinations designed to improve efficacy or address multiple metabolic mechanisms. Products optimized for patients with type 2 diabetes, cardiovascular risk, or other weight-related comorbidities may generate greater clinical value than products positioned only for general weight reduction. Further opportunities are expected in adolescent obesity, long-term weight maintenance, emerging markets with limited access to injectable therapies, and lower-cost generic or differentiated branded products. Companies capable of balancing efficacy, tolerability, dosing convenience, and affordability are positioned to reach patient groups not adequately served by current treatment options.
Challenges
Long-term commercial success will require more than demonstrating statistically significant weight reduction. Developers must establish clinically meaningful differentiation against rapidly improving oral and injectable standards of care, while generating sufficient evidence on treatment durability, safety, discontinuation effects, cardiometabolic outcomes, and use in diverse patient groups. Clinical trials are increasingly expensive and complex as regulators, physicians, and payers seek longer follow-up and broader outcome measures. Companies must also manage large-scale active ingredient production, formulation consistency, quality control, and demand forecasting without compromising regulatory compliance. Competitive intensity may shorten product differentiation cycles and increase marketing, patient-support, and contracting expenditure. Meanwhile, public concern regarding inappropriate cosmetic use, unapproved compounded products, adverse-event management, and unequal access may lead to additional regulatory scrutiny. The market therefore presents substantial demand potential but also requires sustained clinical investment, manufacturing discipline, and carefully managed commercialization.
Industry Chain Analysis
The upstream chain of the Oral Weight Loss Drug market comprises peptide and small-molecule active pharmaceutical ingredients, chemical intermediates, absorption-enhancing agents, release-controlling materials, pharmaceutical-grade excipients, capsule shells, and packaging materials. Technical requirements differ significantly by mechanism. Oral peptide products require specialized formulation strategies to protect active ingredients and improve gastrointestinal absorption, whereas non-peptide small molecules depend more heavily on medicinal chemistry optimization, scalable synthesis, impurity control, and conventional solid-dose manufacturing. Fixed-dose combinations and extended-release products additionally require compatibility studies and release-profile control. The availability, quality, regulatory status, and cost of active ingredients therefore have a direct influence on manufacturing economics and supply reliability.
Midstream activities cover formulation development, tablet compression or capsule filling, coating, analytical testing, clinical development, regulatory registration, commercial manufacturing, and pharmacovigilance. Downstream value is realized through hospitals, specialist clinics, primary-care providers, retail and specialty pharmacies, digital weight-management platforms, and structured chronic-care programs. Innovative originator products capture value through differentiated clinical evidence, intellectual property, brand recognition, and physician adoption, while established brands and generic products compete more strongly through manufacturing efficiency, pricing, channel coverage, and patient accessibility. Across the value chain, the highest barriers are concentrated in mechanism validation, late-stage clinical development, regulatory approval, scalable formulation, and evidence generation supporting long-term treatment value.
Segment Insights
By therapeutic mechanism, GLP-1 receptor agonists have become the most strategically important innovation segment because they narrow the efficacy gap between oral and injectable obesity therapies. Within this category, peptide tablets and small-molecule agonists represent distinct technological and commercial models. Peptide-based products benefit from established incretin biology but require sophisticated absorption technology, while small molecules may provide greater administration flexibility and conventional manufacturing potential. GLP-1/GIP dual receptor agonists and other multi-pathway products represent an emerging development direction, although clinical differentiation and safety remain decisive. Gastrointestinal lipase inhibitors, sympathomimetic appetite suppressants, naltrexone/bupropion combinations, and phentermine/topiramate combinations retain market relevance through established prescribing experience, generic availability, or differentiated patient suitability.
By product class, single-ingredient drugs provide clearer mechanism positioning and simpler clinical evaluation, whereas fixed-dose combinations seek complementary effects through multiple pathways. Originator and branded products account for most innovation value, while generic drugs serve price-sensitive and access-constrained markets. Investigational drugs form an increasingly diverse pipeline covering receptor agonism, intestinal lipid metabolism, and central appetite control. From a dosage-form perspective, immediate-release tablets provide manufacturing simplicity, while extended-release tablets and capsules support controlled exposure and may improve dosing convenience for selected mechanisms. Competitive advantage within each segment will depend on the balance between weight reduction, tolerability, administration requirements, treatment persistence, and total patient cost.
Downstream Market Opportunities
Adult obesity and overweight accompanied by weight-related comorbidities constitute the principal clinical opportunity for Oral Weight Loss Drug products. Within this population, patients with type 2 diabetes, cardiovascular risk factors, dyslipidemia, hypertension, or other metabolic complications may derive particular value from therapies that address both body weight and broader metabolic outcomes. Long-term chronic weight management and maintenance following initial weight reduction are becoming more important than episodic treatment, increasing demand for products with acceptable tolerability and convenient daily administration. Adolescent obesity represents an additional opportunity, although regulatory requirements, safety considerations, and family-supported adherence are more demanding. Oral products may also expand treatment among patients unwilling or unable to use injectable drugs and in healthcare systems where pharmacy-based distribution and primary-care management are more scalable than specialist-led injection programs.
Regional Insights
North America currently represents the most commercially advanced market for next-generation Oral Weight Loss Drug products, supported by early regulatory approvals, established obesity-treatment channels, substantial patient awareness, and rapid commercialization of oral GLP-1 therapies. The United States became the first major market to approve and launch once-daily oral semaglutide for weight management, followed by approval of the small-molecule GLP-1 receptor agonist orforglipron in 2026. This early market access provides important evidence regarding prescription uptake, patient segmentation, pricing, persistence, and competition with injectable products.
Europe offers meaningful demand but is more strongly influenced by health-technology assessment, national reimbursement decisions, prescribing controls, and differences among healthcare systems. Asia-Pacific represents an important longer-term opportunity due to a large population affected by obesity and metabolic disease, expanding domestic drug-development activity, and demand for more accessible oral treatment. China is developing into both a clinical-development base and a potential commercialization market for innovative oral mechanisms, although pricing, reimbursement, regulatory differentiation, and physician education will shape adoption. In other regions, market expansion will depend on affordability, diagnosis rates, healthcare access, and the ability of suppliers to establish reliable local distribution.
Competitive Landscape Analysis
The competitive landscape is transitioning from a relatively established market of gastrointestinal lipase inhibitors, appetite suppressants, and fixed-dose combination products into a broader innovation race involving oral incretin therapies and new metabolic mechanisms. Novo Nordisk and Eli Lilly have established early commercial positions in next-generation oral GLP-1 treatment through approved once-daily products, raising expectations for efficacy and chronic-treatment value. Established oral brands continue to compete through physician familiarity, lower treatment costs, generic availability, and defined patient niches. At the same time, diversified pharmaceutical groups and clinical-stage biotechnology companies in the confirmed participant set are advancing oral GLP-1 receptor agonists, dual receptor candidates, MGAT2 inhibitors, and other mechanism-based products. Competitive positioning is therefore becoming multi-dimensional: leading companies require clinical efficacy and safety data, scalable manufacturing, regulatory execution, reimbursement access, brand credibility, and patient-support capabilities. Companies with less differentiated efficacy may compete through tolerability, flexible administration, combination strategies, regional pricing, or access advantages. As additional candidates progress, head-to-head evidence and real-world treatment persistence are expected to become increasingly important determinants of commercial positioning.
Report Scope
LPI (LP Information)' newest research report, the “Oral Weight Loss Drug Industry Forecast” looks at past sales and reviews total world Oral Weight Loss Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Weight Loss Drug sales for 2026 through 2032. With Oral Weight Loss Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Weight Loss Drug industry.
This Insight Report provides a comprehensive analysis of the global Oral Weight Loss Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Weight Loss Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Weight Loss Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Weight Loss Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Weight Loss Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Weight Loss Drug market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- GLP-1 Receptor Agonists
- Gastrointestinal Lipase Inhibitors
- Sympathomimetic Appetite Suppressants
- Naltrexone/Bupropion Combination Drugs
- Other
Segmentation by Ingredient:
- Single-Ingredient Drugs
- Fixed-Dose Combination Drugs
Segmentation by Dosage Form:
- Immediate-Release Tablets
- Extended-Release Tablets
- Hard Capsules
- Extended-Release Capsules
- Other
Segmentation by Application:
- dult Obesity
- Adolescent Obesity
- Short-Term Weight Reduction
- Long-Term Chronic Weight Management
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Eli Lilly
- Currax Pharmaceuticals
- VIVUS
- Roche
- Structure Therapeutics
- Viking Therapeutics
- Terns Pharmaceuticals
- AstraZeneca
- Merck & Co
- Jiangsu Hengrui Pharmaceuticals
- Huadong Medicine
- Innovent Biologics
- Ascletis Pharma
- Hansoh Pharmaceutical
- Kailera Therapeutics
- Shionogi & Co
- Haleon
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Weight Loss Drug Market Size (2021-2032)
2.1.2 Oral Weight Loss Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oral Weight Loss Drug by Country/Region (2021, 2025 & 2032)
2.2 Oral Weight Loss Drug Segment by Type
2.2.1 GLP-1 Receptor Agonists
2.2.2 Gastrointestinal Lipase Inhibitors
2.2.3 Sympathomimetic Appetite Suppressants
2.2.4 Naltrexone/Bupropion Combination Drugs
2.2.5 Other
2.2.6 Oral Weight Loss Drug Market Size by Type
2.2.6.1 Oral Weight Loss Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
2.3 Oral Weight Loss Drug Segment by Ingredient
2.3.1 Single-Ingredient Drugs
2.3.2 Fixed-Dose Combination Drugs
2.3.3 Oral Weight Loss Drug Market Size by Ingredient
2.3.3.1 Oral Weight Loss Drug Market Size CAGR by Ingredient (2021 VS 2025 VS 2032)
2.3.3.2 Global Oral Weight Loss Drug Market Size Market Share by Ingredient (2021-2026)
2.4 Oral Weight Loss Drug Segment by Dosage Form
2.4.1 Immediate-Release Tablets
2.4.2 Extended-Release Tablets
2.4.3 Hard Capsules
2.4.4 Extended-Release Capsules
2.4.5 Other
2.4.6 Oral Weight Loss Drug Market Size by Dosage Form
2.4.6.1 Oral Weight Loss Drug Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032)
2.4.6.2 Global Oral Weight Loss Drug Market Size Market Share by Dosage Form (2021-2026)
2.5 Oral Weight Loss Drug Segment by Application
2.5.1 dult Obesity
2.5.2 Adolescent Obesity
2.5.3 Short-Term Weight Reduction
2.5.4 Long-Term Chronic Weight Management
2.5.5 Other
2.5.6 Oral Weight Loss Drug Market Size by Application
2.5.6.1 Oral Weight Loss Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
3 ORAL WEIGHT LOSS DRUG MARKET SIZE BY PLAYER
3.1 Oral Weight Loss Drug Market Size Market Share by Player
3.1.1 Global Oral Weight Loss Drug Revenue by Player (2021-2026)
3.1.2 Global Oral Weight Loss Drug Revenue Market Share by Player (2021-2026)
3.2 Global Oral Weight Loss Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ORAL WEIGHT LOSS DRUG BY REGION
4.1 Oral Weight Loss Drug Market Size by Region (2021-2026)
4.2 Global Oral Weight Loss Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Weight Loss Drug Market Size Growth (2021-2026)
4.4 APAC Oral Weight Loss Drug Market Size Growth (2021-2026)
4.5 Europe Oral Weight Loss Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Oral Weight Loss Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oral Weight Loss Drug Market Size by Country (2021-2026)
5.2 Americas Oral Weight Loss Drug Market Size by Type (2021-2026)
5.3 Americas Oral Weight Loss Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Weight Loss Drug Market Size by Region (2021-2026)
6.2 APAC Oral Weight Loss Drug Market Size by Type (2021-2026)
6.3 APAC Oral Weight Loss Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oral Weight Loss Drug Market Size by Country (2021-2026)
7.2 Europe Oral Weight Loss Drug Market Size by Type (2021-2026)
7.3 Europe Oral Weight Loss Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Weight Loss Drug by Region (2021-2026)
8.2 Middle East & Africa Oral Weight Loss Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Oral Weight Loss Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ORAL WEIGHT LOSS DRUG MARKET FORECAST
10.1 Global Oral Weight Loss Drug Forecast by Region (2027-2032)
10.1.1 Global Oral Weight Loss Drug Forecast by Region (2027-2032)
10.1.2 Americas Oral Weight Loss Drug Forecast
10.1.3 APAC Oral Weight Loss Drug Forecast
10.1.4 Europe Oral Weight Loss Drug Forecast
10.1.5 Middle East & Africa Oral Weight Loss Drug Forecast
10.2 Americas Oral Weight Loss Drug Forecast by Country (2027-2032)
10.2.1 United States Market Oral Weight Loss Drug Forecast
10.2.2 Canada Market Oral Weight Loss Drug Forecast
10.2.3 Mexico Market Oral Weight Loss Drug Forecast
10.2.4 Brazil Market Oral Weight Loss Drug Forecast
10.3 APAC Oral Weight Loss Drug Forecast by Region (2027-2032)
10.3.1 China Oral Weight Loss Drug Market Forecast
10.3.2 Japan Market Oral Weight Loss Drug Forecast
10.3.3 Korea Market Oral Weight Loss Drug Forecast
10.3.4 Southeast Asia Market Oral Weight Loss Drug Forecast
10.3.5 India Market Oral Weight Loss Drug Forecast
10.3.6 Australia Market Oral Weight Loss Drug Forecast
10.4 Europe Oral Weight Loss Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Oral Weight Loss Drug Forecast
10.4.2 France Market Oral Weight Loss Drug Forecast
10.4.3 UK Market Oral Weight Loss Drug Forecast
10.4.4 Italy Market Oral Weight Loss Drug Forecast
10.4.5 Russia Market Oral Weight Loss Drug Forecast
10.5 Middle East & Africa Oral Weight Loss Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Oral Weight Loss Drug Forecast
10.5.2 South Africa Market Oral Weight Loss Drug Forecast
10.5.3 Israel Market Oral Weight Loss Drug Forecast
10.5.4 Turkey Market Oral Weight Loss Drug Forecast
10.6 Global Oral Weight Loss Drug Forecast by Type (2027-2032)
10.7 Global Oral Weight Loss Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oral Weight Loss Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Oral Weight Loss Drug Product Offered
11.1.3 Novo Nordisk Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Oral Weight Loss Drug Product Offered
11.2.3 Eli Lilly Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Currax Pharmaceuticals
11.3.1 Currax Pharmaceuticals Company Information
11.3.2 Currax Pharmaceuticals Oral Weight Loss Drug Product Offered
11.3.3 Currax Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Currax Pharmaceuticals Main Business Overview
11.3.5 Currax Pharmaceuticals Latest Developments
11.4 VIVUS
11.4.1 VIVUS Company Information
11.4.2 VIVUS Oral Weight Loss Drug Product Offered
11.4.3 VIVUS Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 VIVUS Main Business Overview
11.4.5 VIVUS Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Oral Weight Loss Drug Product Offered
11.5.3 Roche Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Structure Therapeutics
11.6.1 Structure Therapeutics Company Information
11.6.2 Structure Therapeutics Oral Weight Loss Drug Product Offered
11.6.3 Structure Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Structure Therapeutics Main Business Overview
11.6.5 Structure Therapeutics Latest Developments
11.7 Viking Therapeutics
11.7.1 Viking Therapeutics Company Information
11.7.2 Viking Therapeutics Oral Weight Loss Drug Product Offered
11.7.3 Viking Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Viking Therapeutics Main Business Overview
11.7.5 Viking Therapeutics Latest Developments
11.8 Terns Pharmaceuticals
11.8.1 Terns Pharmaceuticals Company Information
11.8.2 Terns Pharmaceuticals Oral Weight Loss Drug Product Offered
11.8.3 Terns Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Terns Pharmaceuticals Main Business Overview
11.8.5 Terns Pharmaceuticals Latest Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Oral Weight Loss Drug Product Offered
11.9.3 AstraZeneca Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 AstraZeneca Main Business Overview
11.9.5 AstraZeneca Latest Developments
11.10 Merck & Co
11.10.1 Merck & Co Company Information
11.10.2 Merck & Co Oral Weight Loss Drug Product Offered
11.10.3 Merck & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Merck & Co Main Business Overview
11.10.5 Merck & Co Latest Developments
11.11 Jiangsu Hengrui Pharmaceuticals
11.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product Offered
11.11.3 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
11.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
11.12 Huadong Medicine
11.12.1 Huadong Medicine Company Information
11.12.2 Huadong Medicine Oral Weight Loss Drug Product Offered
11.12.3 Huadong Medicine Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Huadong Medicine Main Business Overview
11.12.5 Huadong Medicine Latest Developments
11.13 Innovent Biologics
11.13.1 Innovent Biologics Company Information
11.13.2 Innovent Biologics Oral Weight Loss Drug Product Offered
11.13.3 Innovent Biologics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Innovent Biologics Main Business Overview
11.13.5 Innovent Biologics Latest Developments
11.14 Ascletis Pharma
11.14.1 Ascletis Pharma Company Information
11.14.2 Ascletis Pharma Oral Weight Loss Drug Product Offered
11.14.3 Ascletis Pharma Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Ascletis Pharma Main Business Overview
11.14.5 Ascletis Pharma Latest Developments
11.15 Hansoh Pharmaceutical
11.15.1 Hansoh Pharmaceutical Company Information
11.15.2 Hansoh Pharmaceutical Oral Weight Loss Drug Product Offered
11.15.3 Hansoh Pharmaceutical Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Hansoh Pharmaceutical Main Business Overview
11.15.5 Hansoh Pharmaceutical Latest Developments
11.16 Kailera Therapeutics
11.16.1 Kailera Therapeutics Company Information
11.16.2 Kailera Therapeutics Oral Weight Loss Drug Product Offered
11.16.3 Kailera Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Kailera Therapeutics Main Business Overview
11.16.5 Kailera Therapeutics Latest Developments
11.17 Shionogi & Co
11.17.1 Shionogi & Co Company Information
11.17.2 Shionogi & Co Oral Weight Loss Drug Product Offered
11.17.3 Shionogi & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Shionogi & Co Main Business Overview
11.17.5 Shionogi & Co Latest Developments
11.18 Haleon
11.18.1 Haleon Company Information
11.18.2 Haleon Oral Weight Loss Drug Product Offered
11.18.3 Haleon Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Haleon Main Business Overview
11.18.5 Haleon Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Weight Loss Drug Market Size (2021-2032)
2.1.2 Oral Weight Loss Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oral Weight Loss Drug by Country/Region (2021, 2025 & 2032)
2.2 Oral Weight Loss Drug Segment by Type
2.2.1 GLP-1 Receptor Agonists
2.2.2 Gastrointestinal Lipase Inhibitors
2.2.3 Sympathomimetic Appetite Suppressants
2.2.4 Naltrexone/Bupropion Combination Drugs
2.2.5 Other
2.2.6 Oral Weight Loss Drug Market Size by Type
2.2.6.1 Oral Weight Loss Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
2.3 Oral Weight Loss Drug Segment by Ingredient
2.3.1 Single-Ingredient Drugs
2.3.2 Fixed-Dose Combination Drugs
2.3.3 Oral Weight Loss Drug Market Size by Ingredient
2.3.3.1 Oral Weight Loss Drug Market Size CAGR by Ingredient (2021 VS 2025 VS 2032)
2.3.3.2 Global Oral Weight Loss Drug Market Size Market Share by Ingredient (2021-2026)
2.4 Oral Weight Loss Drug Segment by Dosage Form
2.4.1 Immediate-Release Tablets
2.4.2 Extended-Release Tablets
2.4.3 Hard Capsules
2.4.4 Extended-Release Capsules
2.4.5 Other
2.4.6 Oral Weight Loss Drug Market Size by Dosage Form
2.4.6.1 Oral Weight Loss Drug Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032)
2.4.6.2 Global Oral Weight Loss Drug Market Size Market Share by Dosage Form (2021-2026)
2.5 Oral Weight Loss Drug Segment by Application
2.5.1 dult Obesity
2.5.2 Adolescent Obesity
2.5.3 Short-Term Weight Reduction
2.5.4 Long-Term Chronic Weight Management
2.5.5 Other
2.5.6 Oral Weight Loss Drug Market Size by Application
2.5.6.1 Oral Weight Loss Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
3 ORAL WEIGHT LOSS DRUG MARKET SIZE BY PLAYER
3.1 Oral Weight Loss Drug Market Size Market Share by Player
3.1.1 Global Oral Weight Loss Drug Revenue by Player (2021-2026)
3.1.2 Global Oral Weight Loss Drug Revenue Market Share by Player (2021-2026)
3.2 Global Oral Weight Loss Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ORAL WEIGHT LOSS DRUG BY REGION
4.1 Oral Weight Loss Drug Market Size by Region (2021-2026)
4.2 Global Oral Weight Loss Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Weight Loss Drug Market Size Growth (2021-2026)
4.4 APAC Oral Weight Loss Drug Market Size Growth (2021-2026)
4.5 Europe Oral Weight Loss Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Oral Weight Loss Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oral Weight Loss Drug Market Size by Country (2021-2026)
5.2 Americas Oral Weight Loss Drug Market Size by Type (2021-2026)
5.3 Americas Oral Weight Loss Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Weight Loss Drug Market Size by Region (2021-2026)
6.2 APAC Oral Weight Loss Drug Market Size by Type (2021-2026)
6.3 APAC Oral Weight Loss Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oral Weight Loss Drug Market Size by Country (2021-2026)
7.2 Europe Oral Weight Loss Drug Market Size by Type (2021-2026)
7.3 Europe Oral Weight Loss Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Weight Loss Drug by Region (2021-2026)
8.2 Middle East & Africa Oral Weight Loss Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Oral Weight Loss Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ORAL WEIGHT LOSS DRUG MARKET FORECAST
10.1 Global Oral Weight Loss Drug Forecast by Region (2027-2032)
10.1.1 Global Oral Weight Loss Drug Forecast by Region (2027-2032)
10.1.2 Americas Oral Weight Loss Drug Forecast
10.1.3 APAC Oral Weight Loss Drug Forecast
10.1.4 Europe Oral Weight Loss Drug Forecast
10.1.5 Middle East & Africa Oral Weight Loss Drug Forecast
10.2 Americas Oral Weight Loss Drug Forecast by Country (2027-2032)
10.2.1 United States Market Oral Weight Loss Drug Forecast
10.2.2 Canada Market Oral Weight Loss Drug Forecast
10.2.3 Mexico Market Oral Weight Loss Drug Forecast
10.2.4 Brazil Market Oral Weight Loss Drug Forecast
10.3 APAC Oral Weight Loss Drug Forecast by Region (2027-2032)
10.3.1 China Oral Weight Loss Drug Market Forecast
10.3.2 Japan Market Oral Weight Loss Drug Forecast
10.3.3 Korea Market Oral Weight Loss Drug Forecast
10.3.4 Southeast Asia Market Oral Weight Loss Drug Forecast
10.3.5 India Market Oral Weight Loss Drug Forecast
10.3.6 Australia Market Oral Weight Loss Drug Forecast
10.4 Europe Oral Weight Loss Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Oral Weight Loss Drug Forecast
10.4.2 France Market Oral Weight Loss Drug Forecast
10.4.3 UK Market Oral Weight Loss Drug Forecast
10.4.4 Italy Market Oral Weight Loss Drug Forecast
10.4.5 Russia Market Oral Weight Loss Drug Forecast
10.5 Middle East & Africa Oral Weight Loss Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Oral Weight Loss Drug Forecast
10.5.2 South Africa Market Oral Weight Loss Drug Forecast
10.5.3 Israel Market Oral Weight Loss Drug Forecast
10.5.4 Turkey Market Oral Weight Loss Drug Forecast
10.6 Global Oral Weight Loss Drug Forecast by Type (2027-2032)
10.7 Global Oral Weight Loss Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oral Weight Loss Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Oral Weight Loss Drug Product Offered
11.1.3 Novo Nordisk Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Oral Weight Loss Drug Product Offered
11.2.3 Eli Lilly Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Currax Pharmaceuticals
11.3.1 Currax Pharmaceuticals Company Information
11.3.2 Currax Pharmaceuticals Oral Weight Loss Drug Product Offered
11.3.3 Currax Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Currax Pharmaceuticals Main Business Overview
11.3.5 Currax Pharmaceuticals Latest Developments
11.4 VIVUS
11.4.1 VIVUS Company Information
11.4.2 VIVUS Oral Weight Loss Drug Product Offered
11.4.3 VIVUS Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 VIVUS Main Business Overview
11.4.5 VIVUS Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Oral Weight Loss Drug Product Offered
11.5.3 Roche Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Structure Therapeutics
11.6.1 Structure Therapeutics Company Information
11.6.2 Structure Therapeutics Oral Weight Loss Drug Product Offered
11.6.3 Structure Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Structure Therapeutics Main Business Overview
11.6.5 Structure Therapeutics Latest Developments
11.7 Viking Therapeutics
11.7.1 Viking Therapeutics Company Information
11.7.2 Viking Therapeutics Oral Weight Loss Drug Product Offered
11.7.3 Viking Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Viking Therapeutics Main Business Overview
11.7.5 Viking Therapeutics Latest Developments
11.8 Terns Pharmaceuticals
11.8.1 Terns Pharmaceuticals Company Information
11.8.2 Terns Pharmaceuticals Oral Weight Loss Drug Product Offered
11.8.3 Terns Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Terns Pharmaceuticals Main Business Overview
11.8.5 Terns Pharmaceuticals Latest Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Oral Weight Loss Drug Product Offered
11.9.3 AstraZeneca Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 AstraZeneca Main Business Overview
11.9.5 AstraZeneca Latest Developments
11.10 Merck & Co
11.10.1 Merck & Co Company Information
11.10.2 Merck & Co Oral Weight Loss Drug Product Offered
11.10.3 Merck & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Merck & Co Main Business Overview
11.10.5 Merck & Co Latest Developments
11.11 Jiangsu Hengrui Pharmaceuticals
11.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product Offered
11.11.3 Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
11.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
11.12 Huadong Medicine
11.12.1 Huadong Medicine Company Information
11.12.2 Huadong Medicine Oral Weight Loss Drug Product Offered
11.12.3 Huadong Medicine Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Huadong Medicine Main Business Overview
11.12.5 Huadong Medicine Latest Developments
11.13 Innovent Biologics
11.13.1 Innovent Biologics Company Information
11.13.2 Innovent Biologics Oral Weight Loss Drug Product Offered
11.13.3 Innovent Biologics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Innovent Biologics Main Business Overview
11.13.5 Innovent Biologics Latest Developments
11.14 Ascletis Pharma
11.14.1 Ascletis Pharma Company Information
11.14.2 Ascletis Pharma Oral Weight Loss Drug Product Offered
11.14.3 Ascletis Pharma Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Ascletis Pharma Main Business Overview
11.14.5 Ascletis Pharma Latest Developments
11.15 Hansoh Pharmaceutical
11.15.1 Hansoh Pharmaceutical Company Information
11.15.2 Hansoh Pharmaceutical Oral Weight Loss Drug Product Offered
11.15.3 Hansoh Pharmaceutical Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Hansoh Pharmaceutical Main Business Overview
11.15.5 Hansoh Pharmaceutical Latest Developments
11.16 Kailera Therapeutics
11.16.1 Kailera Therapeutics Company Information
11.16.2 Kailera Therapeutics Oral Weight Loss Drug Product Offered
11.16.3 Kailera Therapeutics Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Kailera Therapeutics Main Business Overview
11.16.5 Kailera Therapeutics Latest Developments
11.17 Shionogi & Co
11.17.1 Shionogi & Co Company Information
11.17.2 Shionogi & Co Oral Weight Loss Drug Product Offered
11.17.3 Shionogi & Co Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Shionogi & Co Main Business Overview
11.17.5 Shionogi & Co Latest Developments
11.18 Haleon
11.18.1 Haleon Company Information
11.18.2 Haleon Oral Weight Loss Drug Product Offered
11.18.3 Haleon Oral Weight Loss Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Haleon Main Business Overview
11.18.5 Haleon Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oral Weight Loss Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oral Weight Loss Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of GLP-1 Receptor Agonists
Table 4. Major Players of Gastrointestinal Lipase Inhibitors
Table 5. Major Players of Sympathomimetic Appetite Suppressants
Table 6. Major Players of Naltrexone/Bupropion Combination Drugs
Table 7. Major Players of Other
Table 8. Oral Weight Loss Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Single-Ingredient Drugs
Table 12. Major Players of Fixed-Dose Combination Drugs
Table 13. Oral Weight Loss Drug Market Size CAGR by Ingredient (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global Oral Weight Loss Drug Market Size by Ingredient (2021-2026) & ($ millions)
Table 15. Global Oral Weight Loss Drug Market Size Market Share by Ingredient (2021-2026)
Table 16. Major Players of Immediate-Release Tablets
Table 17. Major Players of Extended-Release Tablets
Table 18. Major Players of Hard Capsules
Table 19. Major Players of Extended-Release Capsules
Table 20. Major Players of Other
Table 21. Oral Weight Loss Drug Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Oral Weight Loss Drug Market Size by Dosage Form (2021-2026) & ($ millions)
Table 23. Global Oral Weight Loss Drug Market Size Market Share by Dosage Form (2021-2026)
Table 24. Oral Weight Loss Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Global Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Table 27. Global Oral Weight Loss Drug Revenue by Player (2021-2026) & ($ millions)
Table 28. Global Oral Weight Loss Drug Revenue Market Share by Player (2021-2026)
Table 29. Oral Weight Loss Drug Key Players Head office and Products Offered
Table 30. Oral Weight Loss Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 34. Global Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Table 35. Global Oral Weight Loss Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Oral Weight Loss Drug Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Oral Weight Loss Drug Market Size by Country (2021-2026) & ($ millions)
Table 38. Americas Oral Weight Loss Drug Market Size Market Share by Country (2021-2026)
Table 39. Americas Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 40. Americas Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Table 41. Americas Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 42. Americas Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Table 43. APAC Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 44. APAC Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Table 45. APAC Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 46. APAC Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 47. Europe Oral Weight Loss Drug Market Size by Country (2021-2026) & ($ millions)
Table 48. Europe Oral Weight Loss Drug Market Size Market Share by Country (2021-2026)
Table 49. Europe Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 50. Europe Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 51. Middle East & Africa Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 52. Middle East & Africa Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 53. Middle East & Africa Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 54. Key Market Drivers & Growth Opportunities of Oral Weight Loss Drug
Table 55. Key Market Challenges & Risks of Oral Weight Loss Drug
Table 56. Key Industry Trends of Oral Weight Loss Drug
Table 57. Global Oral Weight Loss Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 58. Global Oral Weight Loss Drug Market Size Market Share Forecast by Region (2027-2032)
Table 59. Global Oral Weight Loss Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 60. Global Oral Weight Loss Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 61. Novo Nordisk Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 62. Novo Nordisk Oral Weight Loss Drug Product Offered
Table 63. Novo Nordisk Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Novo Nordisk Main Business
Table 65. Novo Nordisk Latest Developments
Table 66. Eli Lilly Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 67. Eli Lilly Oral Weight Loss Drug Product Offered
Table 68. Eli Lilly Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Eli Lilly Main Business
Table 70. Eli Lilly Latest Developments
Table 71. Currax Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 72. Currax Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 73. Currax Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Currax Pharmaceuticals Main Business
Table 75. Currax Pharmaceuticals Latest Developments
Table 76. VIVUS Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 77. VIVUS Oral Weight Loss Drug Product Offered
Table 78. VIVUS Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. VIVUS Main Business
Table 80. VIVUS Latest Developments
Table 81. Roche Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 82. Roche Oral Weight Loss Drug Product Offered
Table 83. Roche Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Roche Main Business
Table 85. Roche Latest Developments
Table 86. Structure Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 87. Structure Therapeutics Oral Weight Loss Drug Product Offered
Table 88. Structure Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Structure Therapeutics Main Business
Table 90. Structure Therapeutics Latest Developments
Table 91. Viking Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 92. Viking Therapeutics Oral Weight Loss Drug Product Offered
Table 93. Viking Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Viking Therapeutics Main Business
Table 95. Viking Therapeutics Latest Developments
Table 96. Terns Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 97. Terns Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 98. Terns Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Terns Pharmaceuticals Main Business
Table 100. Terns Pharmaceuticals Latest Developments
Table 101. AstraZeneca Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 102. AstraZeneca Oral Weight Loss Drug Product Offered
Table 103. AstraZeneca Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. AstraZeneca Main Business
Table 105. AstraZeneca Latest Developments
Table 106. Merck & Co Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 107. Merck & Co Oral Weight Loss Drug Product Offered
Table 108. Merck & Co Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Merck & Co Main Business
Table 110. Merck & Co Latest Developments
Table 111. Jiangsu Hengrui Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 112. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 113. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Jiangsu Hengrui Pharmaceuticals Main Business
Table 115. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 116. Huadong Medicine Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 117. Huadong Medicine Oral Weight Loss Drug Product Offered
Table 118. Huadong Medicine Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Huadong Medicine Main Business
Table 120. Huadong Medicine Latest Developments
Table 121. Innovent Biologics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 122. Innovent Biologics Oral Weight Loss Drug Product Offered
Table 123. Innovent Biologics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Innovent Biologics Main Business
Table 125. Innovent Biologics Latest Developments
Table 126. Ascletis Pharma Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 127. Ascletis Pharma Oral Weight Loss Drug Product Offered
Table 128. Ascletis Pharma Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Ascletis Pharma Main Business
Table 130. Ascletis Pharma Latest Developments
Table 131. Hansoh Pharmaceutical Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 132. Hansoh Pharmaceutical Oral Weight Loss Drug Product Offered
Table 133. Hansoh Pharmaceutical Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Hansoh Pharmaceutical Main Business
Table 135. Hansoh Pharmaceutical Latest Developments
Table 136. Kailera Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 137. Kailera Therapeutics Oral Weight Loss Drug Product Offered
Table 138. Kailera Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Kailera Therapeutics Main Business
Table 140. Kailera Therapeutics Latest Developments
Table 141. Shionogi & Co Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 142. Shionogi & Co Oral Weight Loss Drug Product Offered
Table 143. Shionogi & Co Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Shionogi & Co Main Business
Table 145. Shionogi & Co Latest Developments
Table 146. Haleon Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 147. Haleon Oral Weight Loss Drug Product Offered
Table 148. Haleon Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 149. Haleon Main Business
Table 150. Haleon Latest Developments
Table 1. Oral Weight Loss Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oral Weight Loss Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of GLP-1 Receptor Agonists
Table 4. Major Players of Gastrointestinal Lipase Inhibitors
Table 5. Major Players of Sympathomimetic Appetite Suppressants
Table 6. Major Players of Naltrexone/Bupropion Combination Drugs
Table 7. Major Players of Other
Table 8. Oral Weight Loss Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Single-Ingredient Drugs
Table 12. Major Players of Fixed-Dose Combination Drugs
Table 13. Oral Weight Loss Drug Market Size CAGR by Ingredient (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global Oral Weight Loss Drug Market Size by Ingredient (2021-2026) & ($ millions)
Table 15. Global Oral Weight Loss Drug Market Size Market Share by Ingredient (2021-2026)
Table 16. Major Players of Immediate-Release Tablets
Table 17. Major Players of Extended-Release Tablets
Table 18. Major Players of Hard Capsules
Table 19. Major Players of Extended-Release Capsules
Table 20. Major Players of Other
Table 21. Oral Weight Loss Drug Market Size CAGR by Dosage Form (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Oral Weight Loss Drug Market Size by Dosage Form (2021-2026) & ($ millions)
Table 23. Global Oral Weight Loss Drug Market Size Market Share by Dosage Form (2021-2026)
Table 24. Oral Weight Loss Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Global Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Table 27. Global Oral Weight Loss Drug Revenue by Player (2021-2026) & ($ millions)
Table 28. Global Oral Weight Loss Drug Revenue Market Share by Player (2021-2026)
Table 29. Oral Weight Loss Drug Key Players Head office and Products Offered
Table 30. Oral Weight Loss Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 34. Global Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Table 35. Global Oral Weight Loss Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Oral Weight Loss Drug Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Oral Weight Loss Drug Market Size by Country (2021-2026) & ($ millions)
Table 38. Americas Oral Weight Loss Drug Market Size Market Share by Country (2021-2026)
Table 39. Americas Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 40. Americas Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Table 41. Americas Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 42. Americas Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Table 43. APAC Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 44. APAC Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Table 45. APAC Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 46. APAC Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 47. Europe Oral Weight Loss Drug Market Size by Country (2021-2026) & ($ millions)
Table 48. Europe Oral Weight Loss Drug Market Size Market Share by Country (2021-2026)
Table 49. Europe Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 50. Europe Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 51. Middle East & Africa Oral Weight Loss Drug Market Size by Region (2021-2026) & ($ millions)
Table 52. Middle East & Africa Oral Weight Loss Drug Market Size by Type (2021-2026) & ($ millions)
Table 53. Middle East & Africa Oral Weight Loss Drug Market Size by Application (2021-2026) & ($ millions)
Table 54. Key Market Drivers & Growth Opportunities of Oral Weight Loss Drug
Table 55. Key Market Challenges & Risks of Oral Weight Loss Drug
Table 56. Key Industry Trends of Oral Weight Loss Drug
Table 57. Global Oral Weight Loss Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 58. Global Oral Weight Loss Drug Market Size Market Share Forecast by Region (2027-2032)
Table 59. Global Oral Weight Loss Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 60. Global Oral Weight Loss Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 61. Novo Nordisk Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 62. Novo Nordisk Oral Weight Loss Drug Product Offered
Table 63. Novo Nordisk Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Novo Nordisk Main Business
Table 65. Novo Nordisk Latest Developments
Table 66. Eli Lilly Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 67. Eli Lilly Oral Weight Loss Drug Product Offered
Table 68. Eli Lilly Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Eli Lilly Main Business
Table 70. Eli Lilly Latest Developments
Table 71. Currax Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 72. Currax Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 73. Currax Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Currax Pharmaceuticals Main Business
Table 75. Currax Pharmaceuticals Latest Developments
Table 76. VIVUS Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 77. VIVUS Oral Weight Loss Drug Product Offered
Table 78. VIVUS Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. VIVUS Main Business
Table 80. VIVUS Latest Developments
Table 81. Roche Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 82. Roche Oral Weight Loss Drug Product Offered
Table 83. Roche Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Roche Main Business
Table 85. Roche Latest Developments
Table 86. Structure Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 87. Structure Therapeutics Oral Weight Loss Drug Product Offered
Table 88. Structure Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Structure Therapeutics Main Business
Table 90. Structure Therapeutics Latest Developments
Table 91. Viking Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 92. Viking Therapeutics Oral Weight Loss Drug Product Offered
Table 93. Viking Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Viking Therapeutics Main Business
Table 95. Viking Therapeutics Latest Developments
Table 96. Terns Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 97. Terns Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 98. Terns Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Terns Pharmaceuticals Main Business
Table 100. Terns Pharmaceuticals Latest Developments
Table 101. AstraZeneca Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 102. AstraZeneca Oral Weight Loss Drug Product Offered
Table 103. AstraZeneca Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. AstraZeneca Main Business
Table 105. AstraZeneca Latest Developments
Table 106. Merck & Co Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 107. Merck & Co Oral Weight Loss Drug Product Offered
Table 108. Merck & Co Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Merck & Co Main Business
Table 110. Merck & Co Latest Developments
Table 111. Jiangsu Hengrui Pharmaceuticals Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 112. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Product Offered
Table 113. Jiangsu Hengrui Pharmaceuticals Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Jiangsu Hengrui Pharmaceuticals Main Business
Table 115. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 116. Huadong Medicine Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 117. Huadong Medicine Oral Weight Loss Drug Product Offered
Table 118. Huadong Medicine Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Huadong Medicine Main Business
Table 120. Huadong Medicine Latest Developments
Table 121. Innovent Biologics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 122. Innovent Biologics Oral Weight Loss Drug Product Offered
Table 123. Innovent Biologics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Innovent Biologics Main Business
Table 125. Innovent Biologics Latest Developments
Table 126. Ascletis Pharma Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 127. Ascletis Pharma Oral Weight Loss Drug Product Offered
Table 128. Ascletis Pharma Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Ascletis Pharma Main Business
Table 130. Ascletis Pharma Latest Developments
Table 131. Hansoh Pharmaceutical Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 132. Hansoh Pharmaceutical Oral Weight Loss Drug Product Offered
Table 133. Hansoh Pharmaceutical Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Hansoh Pharmaceutical Main Business
Table 135. Hansoh Pharmaceutical Latest Developments
Table 136. Kailera Therapeutics Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 137. Kailera Therapeutics Oral Weight Loss Drug Product Offered
Table 138. Kailera Therapeutics Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Kailera Therapeutics Main Business
Table 140. Kailera Therapeutics Latest Developments
Table 141. Shionogi & Co Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 142. Shionogi & Co Oral Weight Loss Drug Product Offered
Table 143. Shionogi & Co Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Shionogi & Co Main Business
Table 145. Shionogi & Co Latest Developments
Table 146. Haleon Details, Company Type, Oral Weight Loss Drug Area Served and Its Competitors
Table 147. Haleon Oral Weight Loss Drug Product Offered
Table 148. Haleon Oral Weight Loss Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 149. Haleon Main Business
Table 150. Haleon Latest Developments
LIST OF FIGURES
Figure 1. Oral Weight Loss Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oral Weight Loss Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oral Weight Loss Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oral Weight Loss Drug Sales Market Share by Country/Region (2025)
Figure 8. Oral Weight Loss Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oral Weight Loss Drug Market Size Market Share by Type in 2025
Figure 10. Global Oral Weight Loss Drug Market Size Market Share by Ingredient in 2025
Figure 11. Global Oral Weight Loss Drug Market Size Market Share by Dosage Form in 2025
Figure 12. Oral Weight Loss Drug in dult Obesity
Figure 13. Global Oral Weight Loss Drug Market: dult Obesity (2021-2026) & ($ millions)
Figure 14. Oral Weight Loss Drug in Adolescent Obesity
Figure 15. Global Oral Weight Loss Drug Market: Adolescent Obesity (2021-2026) & ($ millions)
Figure 16. Oral Weight Loss Drug in Short-Term Weight Reduction
Figure 17. Global Oral Weight Loss Drug Market: Short-Term Weight Reduction (2021-2026) & ($ millions)
Figure 18. Oral Weight Loss Drug in Long-Term Chronic Weight Management
Figure 19. Global Oral Weight Loss Drug Market: Long-Term Chronic Weight Management (2021-2026) & ($ millions)
Figure 20. Oral Weight Loss Drug in Other
Figure 21. Global Oral Weight Loss Drug Market: Other (2021-2026) & ($ millions)
Figure 22. Global Oral Weight Loss Drug Market Size Market Share by Application in 2025
Figure 23. Global Oral Weight Loss Drug Revenue Market Share by Player in 2025
Figure 24. Global Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Figure 25. Americas Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 26. APAC Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 27. Europe Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 29. Americas Oral Weight Loss Drug Value Market Share by Country in 2025
Figure 30. United States Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Oral Weight Loss Drug Market Size Market Share by Region in 2025
Figure 35. APAC Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 36. APAC Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 37. China Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 41. India Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Oral Weight Loss Drug Market Size Market Share by Country in 2025
Figure 44. Europe Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 45. Europe Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 46. Germany Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. France Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 60. APAC Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 61. Europe Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 63. United States Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 64. Canada Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 65. Mexico Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 66. Brazil Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 67. China Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 68. Japan Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 69. Korea Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 71. India Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 72. Australia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 73. Germany Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 74. France Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 75. UK Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 76. Italy Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 77. Russia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 78. Egypt Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 79. South Africa Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 80. Israel Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 81. Turkey Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 82. Global Oral Weight Loss Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Oral Weight Loss Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 1. Oral Weight Loss Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oral Weight Loss Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oral Weight Loss Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oral Weight Loss Drug Sales Market Share by Country/Region (2025)
Figure 8. Oral Weight Loss Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oral Weight Loss Drug Market Size Market Share by Type in 2025
Figure 10. Global Oral Weight Loss Drug Market Size Market Share by Ingredient in 2025
Figure 11. Global Oral Weight Loss Drug Market Size Market Share by Dosage Form in 2025
Figure 12. Oral Weight Loss Drug in dult Obesity
Figure 13. Global Oral Weight Loss Drug Market: dult Obesity (2021-2026) & ($ millions)
Figure 14. Oral Weight Loss Drug in Adolescent Obesity
Figure 15. Global Oral Weight Loss Drug Market: Adolescent Obesity (2021-2026) & ($ millions)
Figure 16. Oral Weight Loss Drug in Short-Term Weight Reduction
Figure 17. Global Oral Weight Loss Drug Market: Short-Term Weight Reduction (2021-2026) & ($ millions)
Figure 18. Oral Weight Loss Drug in Long-Term Chronic Weight Management
Figure 19. Global Oral Weight Loss Drug Market: Long-Term Chronic Weight Management (2021-2026) & ($ millions)
Figure 20. Oral Weight Loss Drug in Other
Figure 21. Global Oral Weight Loss Drug Market: Other (2021-2026) & ($ millions)
Figure 22. Global Oral Weight Loss Drug Market Size Market Share by Application in 2025
Figure 23. Global Oral Weight Loss Drug Revenue Market Share by Player in 2025
Figure 24. Global Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Figure 25. Americas Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 26. APAC Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 27. Europe Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Oral Weight Loss Drug Market Size 2021-2026 ($ millions)
Figure 29. Americas Oral Weight Loss Drug Value Market Share by Country in 2025
Figure 30. United States Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Oral Weight Loss Drug Market Size Market Share by Region in 2025
Figure 35. APAC Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 36. APAC Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 37. China Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 41. India Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Oral Weight Loss Drug Market Size Market Share by Country in 2025
Figure 44. Europe Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 45. Europe Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 46. Germany Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. France Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Oral Weight Loss Drug Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Oral Weight Loss Drug Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 60. APAC Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 61. Europe Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 63. United States Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 64. Canada Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 65. Mexico Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 66. Brazil Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 67. China Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 68. Japan Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 69. Korea Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 71. India Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 72. Australia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 73. Germany Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 74. France Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 75. UK Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 76. Italy Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 77. Russia Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 78. Egypt Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 79. South Africa Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 80. Israel Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 81. Turkey Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
Figure 82. Global Oral Weight Loss Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Oral Weight Loss Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Oral Weight Loss Drug Market Size 2027-2032 ($ millions)
